Assertio (ASRT) Q1 2025 earnings summary

Executive summary

• Q1 2025 net product sales were $26 million, aligning with full-year guidance, but net loss widened to $13.5 million from $4.5 million year-over-year due to lower sales and higher legal expenses.

• Strategic transformation focused on legal exposure reduction, corporate simplification, and investment in growth assets, with ROLVEDON and Sympazan as core drivers.

• Major legal matters, including opioid litigation, were settled or divested, significantly reducing future legal costs and exposure.

• Divestiture of Assertio Therapeutics in May 2025 eliminated opioid litigation exposure and is expected to result in an $8–9 million loss in Q2 2025.

• Non-core asset divestitures and pursuit of strategic transactions are underway to add growth assets.

Financial highlights

• Q1 2025 product sales: $26 million, down from $31.9 million year-over-year; total revenues reported as $26.5 million.

• ROLVEDON sales: $13.1 million (down from $14.5 million), INDOCIN: $5.5 million (down from $8.7 million), Sympazan: $2.2 million (down from $2.6 million).

• Gross margin: 70% (down from 78% adjusted prior year), aided by reduced inventory write-downs.

• GAAP net loss: $13.5 million (vs. $4.5 million loss prior year); adjusted EBITDA: $0.2 million (vs. $7.4 million prior year).

• Cash and investments: $87.3 million as of March 31, 2025; $96.7 million at end of April.

Outlook and guidance

• Full-year 2025 net product sales and adjusted EBITDA guidance maintained: revenue $108–$123 million, adjusted EBITDA $10–$19 million.

• Guidance not contingent on new business development; will be updated in August if necessary.

• ROLVEDON sales expected to grow as payer coverage expands and hospital penetration increases; Sympazan prescriptions up 6.5% year-over-year.

• Management expects existing liquidity to be sufficient for at least the next 12 months, but may seek additional capital if cash needs increase.

• Ongoing legal expenses and settlements anticipated to remain a significant cash use for the remainder of 2025.